Table 3.
Comparison of study endpoints
| Study endpoint | Ivabradine group (n=37; 33.33%), n (%) | Nonivabradine group (n=74; 66.67%), n (%) | Total (n=111) | P |
|---|---|---|---|---|
| Risk of hospitalization | 23 (62.16) | 54 (72.97) | 77 | 0.24 |
| All cause mortality | 3 (8.11) | 3 (4.05) | 6 | - |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.